Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 4.6% – Should You Buy?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) shares shot up 4.6% during trading on Wednesday. The stock traded as high as $11.03 and last traded at $11.22. Approximately 121,339 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 1,265,104 shares. The stock had previously closed at $10.73.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ZVRA. Citizens Jmp raised their target price on Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 6th. Guggenheim lowered their price objective on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a report on Thursday, August 6th. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Finally, UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Zevra Therapeutics has an average rating of “Buy” and an average target price of $27.14.

Zevra Therapeutics Price Performance

The company has a 50-day moving average of $11.48 and a two-hundred day moving average of $11.37. The company has a market capitalization of $653.22 million, a PE ratio of 11.96 and a beta of 0.98.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%.The business had revenue of $39.66 million during the quarter, compared to analysts’ expectations of $33.88 million. As a group, research analysts anticipate that Zevra Therapeutics, Inc. will post 0.72 EPS for the current year.

Insider Buying and Selling

In other Zevra Therapeutics news, Director Corey Watton sold 12,300 shares of Zevra Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the transaction, the director owned 1,800 shares of the company’s stock, valued at $20,250. The trade was a 87.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Large investors have recently made changes to their positions in the business. AIGH Capital Management LLC purchased a new stake in shares of Zevra Therapeutics during the first quarter worth about $11,184,000. Dimensional Fund Advisors LP increased its position in Zevra Therapeutics by 259.2% in the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after purchasing an additional 400,336 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in Zevra Therapeutics by 116.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after purchasing an additional 206,543 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in Zevra Therapeutics by 16.7% during the first quarter. Janney Montgomery Scott LLC now owns 236,834 shares of the company’s stock valued at $2,207,000 after purchasing an additional 33,951 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Zevra Therapeutics during the second quarter valued at $2,846,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.